Guardant Health shares rose sharply after the company announced positive developments regarding its blood test for colorectal cancer screening. The test, already approved by the FDA for certain populations, aims to increase screening rates by offering a simpler alternative to colonoscopy.

Key Takeaways

  • Guardant Health stock jumped on news related to its blood-based colon cancer test.
  • The test is designed to detect colorectal cancer and advanced adenomas from a simple blood draw.
  • Blood tests could encourage more people to undergo routine screening, potentially catching cancers earlier.
  • The company is still pursuing broader Medicare coverage and guideline inclusion.

What Happened With Guardant Health and Its Colon Cancer Blood Test

According to a report from TheStreet, Guardant Health’s stock climbed after the company shared details about its Shield blood test for colorectal cancer. The test already received FDA approval in 2022 for average-risk adults aged 45 and older. Recent news likely focused on steps toward wider adoption, such as new data, insurance coverage, or clinical guideline updates.

Colorectal cancer is the second leading cause of cancer death in the United States, yet about one in three eligible adults are not screened as recommended. A blood test could remove barriers such as preparation, time off work, and discomfort associated with colonoscopy.

How the Shield Blood Test Works

The Guardant Shield test analyzes circulating tumor DNA (ctDNA) in a blood sample. It looks for DNA fragments shed by colorectal tumors or precancerous polyps. If the test detects certain genetic markers, it signals that a follow-up colonoscopy may be needed.

In clinical studies, the test showed high sensitivity for colorectal cancer, though it is less sensitive for advanced adenomas (precancerous polyps) compared to colonoscopy. The manufacturer emphasizes that the test is a screening tool, not a replacement for colonoscopy when a positive result is found.

Impact on Cancer Screening and Public Health

Public health experts view blood-based screening as a potential game-changer because it is convenient. If more people complete screening, more cancers and polyps can be found early, reducing mortality. The U.S. Preventive Services Task Force recommends screening for adults aged 45 to 75, and several methods are available, including stool tests, colonoscopy, and now blood tests.

However, blood tests are not yet included in all clinical guidelines. The American Cancer Society and the U.S. Multi-Society Task Force currently do not recommend blood tests for average-risk screening, citing limited evidence of clinical benefit in real-world settings. Guardant is working to generate additional data that could lead to broader endorsement.

Market Reaction and Investor Outlook

The stock surge reflects investor optimism that Shield will capture a significant share of the colorectal cancer screening market. The market is large: millions of people who avoid colonoscopy each year could opt for a blood test. Guardant faces competition from other companies developing similar liquid biopsy tests, including Exact Sciences and Freenome.

Investors also watch for reimbursement news. Medicare currently covers Shield for certain beneficiaries, but private insurance coverage is still growing. Full inclusion in national screening guidelines would likely accelerate adoption.

Frequently Asked Questions

How accurate is the Guardant Shield blood test for colon cancer?

In the pivotal ECLIPSE study, the Shield test detected 83% of colorectal cancers overall, with higher sensitivity for later-stage cancers. It correctly identified about 90% of people without cancer (specificity). The test is less effective for detecting advanced precancerous polyps, missing about half of them.

Who should consider a blood test for colon cancer screening?

The FDA approved Shield for average-risk adults aged 45 and older. People with a personal or family history of colorectal cancer, certain genetic syndromes, or inflammatory bowel disease should still undergo colonoscopy. Anyone considering a blood test should discuss it with their doctor to determine the best screening method.

Does insurance cover the Guardant Shield blood test?

Medicare covers Shield for eligible beneficiaries. Coverage by private insurers varies. Guardant offers a patient assistance program and recommends checking with your insurance provider before testing. As guidelines evolve, coverage is expected to expand.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.